A STUDY TO EVALUATE THE EFFICACY OF ORAL TERBINAFINE AND A COMBINATION OF ORAL TERBINAFINE AND TOPICAL SERTACONAZOLE IN TINEA CORPORIS PATIENTS ATTENDING DERMATOLOGY OUTPATIENT DEPARTMENT IN A TERTIARY CARE HOSPITAL, HYDERABAD

SWATHI MIRYALA; M. SNEHA MANJU; PURAM GIRI RAJA; MAHESH KUMAR K.

doi:10.22159/ijpps.2025v17i3.53503

Authors

SWATHI MIRYALA Department of Pharmacology, GMC Vikarabad, Telangana, India
M. SNEHA MANJU Department of Pharmacology, MediCiti Institute of Medical Sciences, Hyderabad, India https://orcid.org/0000-0002-3488-134X
PURAM GIRI RAJA Department of Pharmacology, GMC Nagarkurnool, Telangana, India
MAHESH KUMAR K. Department of Pharmacology, Osmania Medical College, Hyderabad, India https://orcid.org/0000-0001-9568-8191

DOI:

https://doi.org/10.22159/ijpps.2025v17i3.53503

Keywords:

Tinea corporis, Oral terbinafine, Sertaconazole, 4-point rating scale, Clinical cure, Mycological cure

Abstract

Objective: To evaluate the efficacy of Oral Terbinafine (250 mg) and a combination of oral terbinafine (250 mg) and topical sertaconazole (2%) in patients with Tinea corporis, attending Dermatology Out Patient Department (OPD), in a tertiary care centre.

Methods: An open-labelled comparative study was conducted in Dermatology OPD at Osmania General Hospital for 12 months. Patients diagnosed with tinea corporis were randomly assigned into two groups: Group A: 50 Patients received Oral Terbinafine (250 mg) and Group B: 50 Patients received combination of Oral Terbinafine (250 mg) & Topical Sertaconazole (2%) for 2 weeks. The patients were advised to come after 1st and 2nd week for follow-up visits.

Results: The study involved 100 patients with tinea corporis, with a mean age of 32.42 ± 8.48 years in Group A and 33.38 ± 7.76 years in Group B. Most participants were males (Group A – 62%, Group B – 80%). Clinical features (itching, burning, scaling, crusting, vesicles, pustules) showed a significant reduction in Group B compared to Group A after 2 weeks of treatment, with a statistically significant difference (P < 0.000001). Lesion size decreased more in Group B (from 26.1 ± 14.9 to 2.0 ± 1.2) than in Group A (from 24.5 ± 14.4 to 6.01 ± 4.2), with a significant difference (P < 0.0000001). All specimens in Group B were free of fungal growth.

Conclusion: Clinical cure and mycological cure were better with a Combination of Oral Terbinafine (250 mg) and Topical Sertaconazole (2%) than with Oral Terbinafine (250 mg) alone. Both drugs were well tolerated and no major adverse drug reactions were noted during the study period.

Downloads

Download data is not yet available.

References

Jartarkar SR, Patil A, Goldust Y, Cockerell CJ, Schwartz RA, Grabbe S, Goldust M. Pathogenesis, Immunology and Management of Dermatophytosis. J Fungi (Basel). 2021 Dec 31;8(1):39. doi: 10.3390/jof8010039. PMID: 35049979; PMCID: PMC8781719.

Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, Godse K, Patel K, Rengasamy M, Rudramurthy S, Dogra S. Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018 Jul 24;18(1):6. doi: 10.1186/s12895-018-0073-1. PMID: 30041646; PMCID: PMC6057051.

Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin. 2003 Jul;21(3):395-400, v. doi: 10.1016/s0733-8635(03)00031-7. PMID: 12956194.

Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J. 2016 Mar-Apr;7(2):77-86. doi: 10.4103/2229-5178.178099. PMID: 27057486; PMCID: PMC4804599.

Naglot A, Shrimali S, Nath B, Gogoi H, Veer V, Chander J, Tewari R. Recent trends of dermatophytosis in Northeast India (Assam) and interpretation with published studies. Int J Curr Microbiol App Sci. 2015;4:111-120..

Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev. 1995 Apr;8(2):240-59. doi: 10.1128/CMR.8.2.240. PMID: 7621400; PMCID: PMC172857.

Faergemann J, Zehender H, Denouël J, Millerioux L. Levels of terbinafine in plasma,stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta DermVenereol. 1993 Aug;73(4):305-9. doi: 10.2340/000155557300304. PMID: 7904107.

Van der Schroeff JG, Cirkel PK, Crijns MB, Van Dijk TJ, Govaert FJ, Groeneweg DA, Tazelaar DJ, De Wit RF, Wuite J. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol. 1992 Feb;126 Suppl 39:36-9. doi: 10.1111/j.1365-2133.1992.tb00008.x. PMID: 1531927.

Goodfield MJ, Rowell NR, Forster RA, Evans EG, Raven A. Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol. 1989 Dec;121(6):753-7. doi: 10.1111/j.1365-2133.1989.tb08217.x. PMID: 2532927.

Poojary SA. Topical antifungals: A review and their role in current management of dermatophytoses. Clin Dermatol Rev. 2017;1(Suppl 1):S24-S29. doi: 10.4103/CDR.CDR_34_17.

Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59. doi: 10.2165/00003495-200969030-00009. PMID: 19275277.

Sumitha A, Geetha M, Shashikala GH, Somashekar HS, Chandan KS. Efficacy and safety of 1% terbinafine hydrochloride versus 2% sertaconazole cream in the treatment of tinea corporis. Int J Basic Clin Pharmacol. 2017;4(3):474-478. doi: 10.18203/2319-2003.ijbcp20150020.

Choudhary S, Bisati S, Singh A, Koley S. Efficacy and Safety of Terbinafine Hydrochloride 1% Cream vs. Sertaconazole Nitrate 2% Cream in Tinea Corporis and Tinea Cruris: A Comparative Therapeutic Trial. Indian J Dermatol. 2013 Nov;58(6):457-60. doi: 10.4103/0019-5154.119958. PMID: 24249898; PMCID: PMC3827518.

Chatterjee D, Ghosh SK, Sen S, Sarkar S, Hazra A, De R. Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study. Indian J Pharmacol. 2016 Nov-Dec;48(6):659-664. doi: 10.4103/0253-7613.194850. PMID: 28066103; PMCID: PMC5155466..

Selvan AT, Gutha G, Vijaybhaskar, Suthakaran R. Comparative evaluation of newer topical antifungal agents in the treatment of superficial fungal infections (tinea or dermatophytic). Int Res J Pharm. 2013;4:224-228.

Jerajani H, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. Indian J Dermatol. 2013 Jan;58(1):34-8. doi: 10.4103/0019-5154.105284. PMID: 23372210; PMCID: PMC3555370.

Siddiqui SM, Phulari YJ, Hiremath RN, Patil C, Patel P. A clinico-mycological evaluation of dermatophytic infections – a single centre prospective observational study. Asian J Pharm Sci Clin Res. 2022 Apr;15(4):122-6. doi: 10.22159/ajpcr.2022.v15i4.44454.

Shekhar A, Mittal G, Chandane RD, Suranagi UD. A prospective randomized open-labeled parallel group study to compare the efficacy of oral terbinafine versus oral terbinafine plus oral fluconazole in dermatophyte infections. Asian J Pharm Sci Clin Res. 2023 May;16(5):104-8. doi: 10.22159/ajpcr.2023.v16i5.47224.